GMS VENTURES & INVESTMENTS 13D and 13G filings for Outlook Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-05-28 5:24 pm Purchase | 2025-05-27 | 13D | Outlook Therapeutics, Inc. OTLK | GMS VENTURES & INVESTMENTS | 29,040,929 50.300% | 12,857,142 (+79.44%) | Filing |
| 2025-03-12 9:11 pm Purchase | 2025-03-11 | 13D | Outlook Therapeutics, Inc. OTLK | GMS VENTURES & INVESTMENTS | 16,183,787 41.600% | 3,458,571 (+27.18%) | Filing |
| 2025-01-22 4:17 pm Purchase | 2025-01-17 | 13D | Outlook Therapeutics, Inc. OTLK | GMS VENTURES & INVESTMENTS | 12,725,216 38.600% | 3,458,571 (+37.32%) | Filing |
| 2024-03-20 5:24 pm Purchase | 2024-03-18 | 13D | Outlook Therapeutics, Inc. OTLK | GMS VENTURES & INVESTMENTS | 9,266,645 37.000% | 9,266,645 (New Position) | Filing |